Even as a small child, I enjoyed watching nature shows. They didn’t come on television often, but when they did, I absorbed every word. At school, I might not have been able to recite the Pythagorean theorem, but I could say with confidence that butterflies taste with their feet. That didn’t help me much in […] The post Finding safety while living with the constant threat of MS progression appeared first on Multiple Sclerosis News Today ..read more

There’s no evidence to suggest that multiple sclerosis (MS) directly causes most cancers, but having the condition may marginally increase the likelihood of developing cervical cancer, according to a new study from China. That study found “no causal relationship between MS and 15 types of cancers except cervical cancer,” the researchers wrote. However, the team […] The post Having MS may marginally increase likelihood of cervical cancer: Study appeared first on Multiple Sclerosis News Today ..read more

People with multiple sclerosis (MS) who are being treated with Tysabri (natalizumab) tend to prefer receiving the medication as a subcutaneous (under-the-skin) injection rather than an intravenous (into-the-vein) infusion, according to new data from an observational study. “Based on current data, there is a trend toward patients’ preference for the natalizumab SC [subcutaneous] route over […] The post MS patients prefer Tysabri injection to intravenous infusion: Study appeared first on Multiple Sclerosis News Today ..read more

Fully 70% of patients with nonactive secondary progressive multiple sclerosis (SPMS) who received foralumab nasal spray in an expanded access program (EAP) experienced a lessening in fatigue levels after six months of treatment. That’s according to early findings from the EAP — a program that enables patients with serious or life-threatening conditions to have access […] The post Foralumab found to ease fatigue in SPMS patients in access program appeared first on Multiple Sclerosis News Today ..read more

Researchers have identified a distinct profile of self-reactive antibodies that appear in the blood years before the first clinical signs of multiple sclerosis (MS), which they believe could be used to help diagnose the neurodegenerative disease. The antibodies were found in about 10% of people who developed MS and were basically 100% predictive of an […] The post Autoantibodies seen in blood years before MS diagnosis: Study appeared first on Multiple Sclerosis News Today ..read more

With this year’s fundraiser, the Multiple Sclerosis Association of America (MSAA) is marking its 10th annual Improving Lives Benefit — an event that shines a light on uplifting members of the multiple sclerosis (MS) community and outstanding corporate partners. The affair will take place on May 15 at the Barnes Foundation, in Philadelphia, and will also […] The post It’s year 10 for MSAA’s upcoming Improving Lives Benefit for MS appeared first on Multiple Sclerosis News Today ..read more

A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical relapses and new or worsening brain lesions, according to one-year data from the Phase 3 OCARINA II study. Given twice a year as a 10-minute injection, this formulation of Ocrevus appears to deliver the same clinical benefit […] The post AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year appeared first on Multiple Sclerosis News Today ..read more

Viatris has launched a generic version of low-dose Copaxone (glatiramer acetate) in the Canadian market for the treatment of people with relapsing-remitting multiple sclerosis (RRMS) who retain the ability to walk. Called Glatiramer Acetate Injection 20 mg/mL, the product was approved in Canada as a generic of Copaxone in September 2023. It’s given as a […] The post Viatris launches low-dose Copaxone generic formulation in Canada appeared first on Multiple Sclerosis News Today ..read more

Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who had not received any prior treatment. That’s according to new data from the ULTIMATE Phase 3 trials, which continue to show that early treatment […] The post AAN 2024: Briumvi found to ease disability in certain MS patients appeared first on Multiple Sclerosis News Today ..read more

Upon commencing my undergraduate studies at the University of Texas (UT) at Austin, I pursued a major in prehealth neuroscience. I had decided to pursue this degree shortly after my diagnosis of relapsing-remitting multiple sclerosis in 2016, during my senior year of high school. My hope in choosing the medical field was to understand multiple sclerosis […] The post Learning to manage cognitive impairment with multiple sclerosis appeared first on Multiple Sclerosis News Today ..read more